Nine advisory committee members voted against Capricor’s Duchenne muscular dystrophy therapy on Tuesday. Three voted for it. The FDA’s own briefing document had called the primary evidence unconvincing before a single panelist spoke, and a nearly identical scene is playing out for a different company on the same regulatory stage today. Altimmune, meanwhile, needed no committee at all. Its alcohol use disorder drug simply worked.
Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Committee for Duchenne Cardiomyopathy
Capricor Therapeutics (Nasdaq: CAPR) went into Tuesday’s FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting hoping for validation of years of clinical work on deramiocel, a cell therapy for the cardiac complications of Duchenne muscular dystrophy. The panel voted 9 to 3 against it. The single question on the table was whether the Phase 3 HOPE-3 trial provided substantial evidence of effectiveness for cardiomyopathy in DMD. Nine panelists said no.
The dispute at the center of the meeting was not really about the drug. It was about which statistical analysis plan governed the results. Capricor says its results are locked to SAP version 3.0, finalized before the trial was unblinded, and that this version shows a statistically significant primary endpoint win. The FDA’s briefing document leaned on what the agency itself called an unsigned, incomplete internal draft, SAP version 1.1, and concluded the evidence does not demonstrate efficacy. Two parties, same trial, opposite conclusions about which version of the analysis to trust. Neither reviewer flagged a safety concern; this was purely a fight over efficacy evidence.
This is Capricor’s second rejection scenario for deramiocel; the FDA issued a Complete Response Letter in 2025 before the company resubmitted with the HOPE-3 data. The current PDUFA target action date is August 22, 2026, and the agency has said it will not issue a final decision until it has weighed the panel’s non-binding recommendation. A second CRL is now a credible outcome. Capricor said in a statement it “strongly disagrees” with the agency’s characterization of the evidence. The stock had already fallen roughly 70% into the meeting on the negative briefing document alone, so Tuesday’s vote confirmed a decline the market had mostly priced in already.
Replimune’s RP1 Faces a Third FDA Advisory Committee After Two Prior Rejections
Replimune Group (Nasdaq: REPL) faces its own FDA advisory committee today, one day after Capricor’s, for a melanoma therapy already rejected by the agency twice. RP1 (vusolimogene oderparepvec), combined with Bristol Myers Squibb’s nivolumab, is under review for advanced melanoma in patients who progressed on prior anti-PD-1 therapy.
FDA staff released briefing documents days before the meeting calling the single-arm IGNYTE trial data “not interpretable”, and the stock fell as much as 38% over two sessions in response. Replimune’s own argument is that randomizing this specific patient population, people who had already failed the only approved therapy for their disease, would have been unethical, since a control arm would have offered them nothing meaningful to compare against. BMO called it an “uphill battle” for the company heading into today’s meeting.
As of this writing, the committee’s vote had not yet been announced; this article will be updated once the outcome is known. The FDA’s PDUFA target action date for a final decision is August 2, 2026, three days after today’s meeting.
Cash matters here too. Replimune’s reserves are expected to fund operations only into early 2027, and the company has disclosed that failing to win accelerated approval could force it to halt RP1’s melanoma development and restructure its broader pipeline.
Altimmune’s Pemvidutide Hits Primary Endpoint in Alcohol Use Disorder Phase 2 Trial
Altimmune (Nasdaq: ALT) had a considerably quieter week. On July 28, the company reported that pemvidutide, its dual glucagon/GLP-1 receptor agonist, met the primary endpoint of the Phase 2 RECLAIM trial in moderate to severe alcohol use disorder, with a statistically significant reduction in heavy drinking days compared to placebo. Patients on the drug averaged 4.20 fewer heavy drinking days per week at 24 weeks, against a 2.75-day reduction in the placebo arm.
Two of the secondary endpoints, zero heavy drinking days and a two-level reduction on the World Health Organization Risk Drinking Levels scale, are FDA-recognized registrational endpoints, meaning Altimmune has an agency-sanctioned path to a pivotal program rather than a data package it has to convince the FDA to accept on its own terms. Only three drugs are approved for alcohol use disorder in the US, and fewer than 2% of patients with the disorder use any of them, so the commercial opportunity here is largely uncontested if the drug gets there.
Pemvidutide carries Fast Track designation for both AUD and MASH, and Breakthrough Therapy designation for MASH. None of those are approvals; they speed up FDA review timelines, nothing more. William Blair flagged that a full pivotal AUD program, alongside Altimmune’s ongoing MASH and alcohol-associated liver disease work, will likely require additional capital beyond the company’s current cash position. Altimmune held $535 million in cash as of April 30. The company plans to request an end-of-Phase 2 meeting with the FDA to map out next steps.
Replimune’s August 2 PDUFA Date, Capricor’s Next Step, and Altimmune’s FDA Meeting to Watch
Replimune’s FDA decision is due August 2, three days after today’s advisory vote, whatever that vote turns out to be. Capricor has not yet said whether it will pursue a Type A meeting or an additional data package if the FDA does issue a second CRL, but its August 22 PDUFA date is now clouded by the panel’s near-unanimous rejection. Altimmune will request its end-of-Phase 2 meeting with the FDA in the coming weeks, and the design of any registrational AUD trial will depend on what comes out of that conversation.
Sources
- FierceBiotech: FDA adcomm shoots down Capricor’s Duchenne cell therapy after meeting marked by statistical dispute, July 29, 2026
- AllSci: FDA briefing casts doubt on Capricor’s deramiocel ahead of DMD AdCom, July 27, 2026
- Capricor Therapeutics / GlobeNewswire: Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel, July 27, 2026
- BioSpace: FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm, July 28, 2026
- Investing.com: Why is Replimune stock plunging today, July 28, 2026
- PharmExec: Replimune Shares Crash Following FDA Review of Melanoma Treatment, July 28-30, 2026
- Altimmune / BioSpace: Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder, July 28, 2026
- AllSci: Altimmune’s pemvidutide sees clear path forward in alcohol use disorder after strong Phase II, July 29, 2026
- FierceBiotech: Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win, July 28, 2026
Editorial Disclosure
This article is based entirely on publicly available information including company press releases, FDA advisory committee briefing documents, and contemporaneous news coverage. Securities discussed include Capricor Therapeutics, Inc. (Nasdaq: CAPR), Replimune Group, Inc. (Nasdaq: REPL), and Altimmune, Inc. (Nasdaq: ALT). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Capricor’s deramiocel: the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9 to 3 against a finding of substantial evidence of effectiveness for cardiomyopathy in Duchenne muscular dystrophy on July 29, 2026. This vote is non-binding; the FDA has not yet issued a final decision on the BLA resubmission, and the PDUFA target action date is August 22, 2026. The dispute centers on which statistical analysis plan version governs the trial’s primary endpoint result; Capricor disputes the FDA’s characterization of the evidence and has stated its own results rely on a different, later-finalized SAP version. No safety signal was raised in connection with this vote. A second Complete Response Letter is a credible outcome and should not be assumed away by this disclosure. Replimune’s RP1: the FDA advisory committee meeting for RP1 in advanced melanoma is scheduled for July 30, 2026, and the outcome was not known at the time this article was written. RP1 has previously received two Complete Response Letters, in July 2025 and April 2026. FDA staff briefing documents released ahead of the meeting characterized the supporting trial data as “not interpretable.” The PDUFA target action date is August 2, 2026. Replimune has disclosed that its cash is expected to fund operations only into early 2027 and that failure to secure approval could force a halt to RP1’s melanoma development and a restructuring of its broader pipeline. RP1 is investigational and has not been approved by the FDA for any indication. Altimmune’s pemvidutide: topline Phase 2 results announced July 28, 2026 are based on a company-reported analysis and have not yet been peer-reviewed or published; results are planned for presentation at a medical conference and submission to a peer-reviewed journal. Pemvidutide is investigational and has not been approved by the FDA for any indication. Fast Track and Breakthrough Therapy designations referenced in this article expedite FDA review timelines and do not indicate or guarantee eventual approval. A named analyst estimate regarding Altimmune’s future capital needs for a full AUD pivotal program is cited and linked to its original source; aktiego.com does not independently verify analyst research. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
